HC Wainwright Expects Reduced Earnings for scPharmaceuticals

scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) - Stock analysts at HC Wainwright decreased their FY2024 earnings estimates for scPharmaceuticals in a report released on Thursday, November 14th. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($1.43) per share for the year, down from their prior estimate of ($1.33). HC Wainwright has a "Buy" rating and a $18.00 price objective on the stock. The consensus estimate for scPharmaceuticals' current full-year earnings is ($1.37) per share. HC Wainwright also issued estimates for scPharmaceuticals' Q4 2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($0.19) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.83) EPS, FY2026 earnings at ($0.29) EPS, FY2027 earnings at $0.20 EPS and FY2028 earnings at $0.45 EPS.

Separately, Craig Hallum reduced their target price on shares of scPharmaceuticals from $16.00 to $12.00 and set a "buy" rating for the company in a research report on Thursday.

scPharmaceuticals Price Performance

NASDAQ:SCPH traded down $0.14 during trading hours on Monday, reaching $3.32. 251,984 shares of the company were exchanged, compared to its average volume of 270,889. The company has a current ratio of 8.08, a quick ratio of 3.66 and a debt-to-equity ratio of 1.66. The stock's 50-day moving average is $4.46 and its 200-day moving average is $4.48. The firm has a market cap of $166.13 million, a PE ratio of -1.82 and a beta of 0.15. scPharmaceuticals has a twelve month low of $3.08 and a twelve month high of $6.71.

Institutional Investors Weigh In On scPharmaceuticals

A number of hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets increased its position in scPharmaceuticals by 116.9% during the third quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company's stock worth $26,000 after purchasing an additional 3,101 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new stake in scPharmaceuticals during the third quarter worth about $57,000. MetLife Investment Management LLC increased its position in scPharmaceuticals by 135.0% during the third quarter. MetLife Investment Management LLC now owns 16,974 shares of the company's stock worth $77,000 after purchasing an additional 9,752 shares during the last quarter. Captrust Financial Advisors increased its position in scPharmaceuticals by 32.2% during the third quarter. Captrust Financial Advisors now owns 18,539 shares of the company's stock worth $85,000 after purchasing an additional 4,513 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in scPharmaceuticals during the first quarter worth about $90,000. 89.52% of the stock is currently owned by institutional investors and hedge funds.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.